Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

9.320 +0.320 (+3.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum. 
Via Chartmill
Earnings Scheduled For November 4, 2025
 
Via Benzinga
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
Amicus (FOLD) Q2 Revenue Jumps 22%
Via The Motley Fool
Topics Intellectual Property
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally. 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Amicus Therapeutics Earnings Preview
 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
 
Via Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
 
Via Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
 
Via Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
 
Via Benzinga
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
 
Via Benzinga
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
 
Via Benzinga
The Analyst Landscape: 4 Takes On Amicus Therapeutics
 
Via Benzinga
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
 
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
Via Benzinga
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.